BIOGEN INC.

(BIIB)
  Report
Delayed Nasdaq  -  04:00 2022-06-24 pm EDT
211.93 USD   +0.26%
06/24Biogen Terminates Alzheimer's Drug Aduhelm Study Over Coverage Limits
MT
06/24BIOGEN INC.(NASDAQGS : BIIB) added to Russell Midcap Value Index
CI
06/24BIOGEN INC.(NASDAQGS : BIIB) dropped from Russell Top 200 Value Index
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Most relevant news about BIOGEN INC.
06/24Biogen Terminates Alzheimer's Drug Aduhelm Study Over Coverage Limits
MT
06/24BIOGEN INC.(NASDAQGS : BIIB) added to Russell Midcap Value Index
CI
06/24BIOGEN INC.(NASDAQGS : BIIB) dropped from Russell Top 200 Value Index
CI
06/24BIOGEN INC.(NASDAQGS : BIIB) dropped from Russell Top 200 Index
CI
06/24BIOGEN INC.(NASDAQGS : BIIB) added to Russell Midcap Index
CI
06/22Biogen, Happify Health Team Up to Offer Digital Services for Multiple Sclerosis Patient..
MT
06/22Biogen Inc. - European Patent Office Grants Patent Related to TECFIDERA (Dimethyl Fumar..
AQ
06/22Biogen and Happify Health Collaborate to Support Multiple Sclerosis Patients on Digital..
BU
06/22Biogen and Happify Health Collaborates to Support Multiple Sclerosis Patients on Digita..
CI
06/21Chirfi Guindo, Executive Vice President for Global Product Strategy and Commercializati..
CI
06/21European Patent Office Grants Patent Related to TECFIDERA® (Dimethyl Fumarate)
GL
06/16Biogen Inc. - New Data Presented at Cure SMA Reveal Residual Unmet Needs in Young SMA P..
AQ
06/15Karyopharm Therapeutics Says Biogen Scraps KPT-350 Deal from 2018
MT
06/15BIOGEN : Annual Stockholder Presentation 2022
PU
06/15BIOGEN : Appreciation Statement for Retiring Board Members Nancy Leaming and Brian Posner
PU
06/15New Data Presented at Cure SMA Reveal Residual Unmet Needs in Young SMA Patients Treate..
GL
06/15New Data Presented at Cure SMA Reveal Residual Unmet Needs in Young SMA Patients Treate..
AQ
06/15Biogen Inc. Presents New Data from Clinical Studies Aimed at Assessing Remaining Unmet ..
CI
06/14The Biogen Foundation and Community Lab Celebrates 20 Years of Serving our Communities
GL
06/08Biogen Bows Out of Conference Over 'COVID Considerations'
MT
06/08Biogen And Samsung Bioepis Launch BYOOVIZ (ranibizumab-nuna)
AQ
06/08BIOGEN : Withdrawal from the Jefferies Healthcare Conference
PU
06/06Biogen Agrees to Develop, Commercialize Alectos Therapeutics' AL01811 for Parkinson's ..
MT
06/06Biogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar..
AQ
06/06Biogen Inc. - New 12-Month Tofersen Data Presented at ENCALS Meeting Show Clinically Me..
AQ
06/06AMGEN : FDA OK's Riabni Biosimilar to Rituxan in Rheumatoid Arthritis
DJ
06/06Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL0181..
GL
06/06Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL0181..
AQ
06/06Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for Al0181..
CI
06/03Biogen, Bio-Thera Report Phase 3 Data for Tocilizumab Biosimilar Candidate
MT
06/03Biogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar..
GL
06/03Biogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar..
AQ
06/03Biogen Inc. and Bio-Thera Solutions, Ltd. Present Positive Phase 3 Data for Tocilizumab..
CI
06/03Biogen Phase 3 Trial Shows Clinical Benefit of Tofersen in ALS Patients
MT
06/03New 12-Month Tofersen Data Presented at ENCALS Meeting Show Clinically Meaningful Benef..
GL
06/03New 12-Month Tofersen Data Presented at ENCALS Meeting Show Clinically Meaningful Benef..
AQ
06/03Biogen Inc. Announces New 12-Month Data for Tofersen
CI
06/02Biogen, Samsung Bioepis' Byooviz Launches in US
MT
06/02Biogen and Samsung Bioepis' BYOOVIZ™ (ranibizumab-nuna) Launches in the United St..
AQ
06/02Biogen Inc. and Samsung Bioepis Co., Ltd.’ BYOOVIZ™ (Ranibizumab-Nuna) Launch..
CI
06/01WALL STREET STOCK EXCHANGE : Wall Street starts a new chapter
06/01Sage Therapeutics, Biogen Say Phase 3 Study of Postpartum Depression Treatment Met Prim..
MT
06/01Sage-Biogen drug improves symptoms in postpartum depression study
RE
06/01Sage, Biogen's drug meets main goal in postpartum depression study
RE
06/01Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in P..
CI
06/01SAGE, BIOGEN : Zuranolone Hits Key Goals in Postpartum Depression
DJ
05/31Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor..
AQ
05/31Denali Therapeutics and Biogen Announce Initiation of Phase 2B Study of Lrrk2 Inhibitor..
CI
05/27BIOGEN : to Participate in the Jefferies Healthcare Conference
PU
05/23MARKETSCREENER'S WORLD PRESS REVIEW : May 23, 2022
05/12Roche believes cancer drug setback not a fatal blow to growth prospects
RE
05/10Biogen Says Eisai Submits Biologics License Application for Lecanemab for Alzheimer's D..
MT
05/09Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of..
CI
05/05Japanese shares rise on energy, financials boost
RE
05/05Biogen Partners With MedRhythms to Develop, Commercialize Potential Treatment for Gait ..
MT
05/05Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic T..
BU
05/05Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic T..
GL
05/05Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic T..
AQ
05/05Biogen and MedRhythms to Develop and Commercialize A Prescription Digital Therapeutic T..
CI
05/05Xbrane Biopharma releases interim report for January – March 2022
AQ
05/04Michel Vounatsos to Step Down as Chief Executive Officer of Biogen
CI
05/04Morgan Stanley Adjusts Biogen's Price Target to $285 from $283, Keeps Overweight Rating
MT
05/04Oppenheimer Adjusts Biogen Price Target to $225 From $240, Maintains Outperform Rating
MT
05/04MARKETSCREENER'S WORLD PRESS REVIEW : May 4, 2022
05/04RBC Raises Price Target on Biogen to $251 From $244, Maintains Outperform Rating
MT
05/04Barclays Adjusts Biogen's Price Target to $210 From $219, Keeps Equalweight Rating
MT
05/04Wedbush Trims Biogen's Price Target to $185 From $188, Citing Aduhelm Wind-Down, Mainta..
MT
05/03Tranche Update on Biogen Inc.'s Equity Buyback Plan announced on October 21, 2020.
CI
05/03Change at the top for Biogen after Alzheimer's drug flops
AQ
05/03Biogen's Quarterly Results Fall as Drugmaker Plans to Stop Selling Aduhelm; CEO to Step..
MT
05/03TIMELINE-Biogen CEO to leave as Alzheimer's drug struggles
RE
05/03GLOBAL MARKETS LIVE : BP, Pfizer, Expedia, Citigroup, Amazon...
05/03WALL STREET STOCK EXCHANGE : Nervousness is apparent ahead of Fed speech
05/03SECTOR UPDATE : Health Care Stocks Mixed Premarket Tuesday
MT
05/03Biogen Q1 Non-GAAP EPS, Revenue Drop; CEO Michel Vounatsos to Leave; Reaffirms 2022 Gui..
MT
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on BIOGEN INC.